Lupin Gains on USFDA Approval for Modafinil Tablets

Lupin is in focus after receiving USFDA approval for Modafinil Tablets USP 100 mg and 200 mg, expanding its product portfolio in the US market. The tablets are bioequivalent to Provigil, the reference listed drug. The approval is positive for Lupin’s US generics business and adds another product to its CNS portfolio. The company continues to strengthen its presence in the US through new product launches and regulatory approvals. Lupin also reported strong Q1 FY27 performance, with revenue rising 32% YoY to ₹8,276.89 crore and operating profit increasing 41.8% YoY to ₹2,449.53 crore. Net profit stood at ₹1,416.98 crore, up 16% YoY. With strong earnings growth and continued US product approvals, Lupin’s growth outlook remains positive. However, investors will monitor US pricing pressure, regulatory developments and margin sustainability in the coming quarters.